Apollo Awaits First Proof-Of-Concept Data For Atopic Dermatitis Drug

 
• By Andrew McConaghie

Having built its portfolio from university collaborations and targeted in-licensing, the UK firm now hopes to validate its business model with Phase II readouts in 2025.

Apollo Therapeutics is working with leading UK universities to translate research into novel drugs, but is also in-licensing biopharma assets. (Shutterstock)

More from Start-Ups & SMEs

More from Alimentary/Metabolic